Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | EIF2AK4 | Q9P2K8 | 3/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16023804 | 0.82 | EIF2AK4 (0.54) | EIF2AK4 | |
| SCHEMBL25272927 | 0.72 | CYP1A2 (0.45) | PI4KAPI4KBALDH1A1LMNA | |
| SCHEMBL1643374 | 0.69 | DHFR (0.49) | ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL28281841 | 0.68 | DHFR (0.49) | PIK3CAPI4KAPIK3CGADORA2AADORA1 | |
| SCHEMBL25422454 | 0.67 | MAPT (0.44) | KDM4EALDH1A1LMNAMAPTPKM | |
| SCHEMBL17393506 | 0.65 | PIK3CG (0.36) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL25275632 | 0.65 | ALDH1A1 (0.47) | ALDH1A1LMNA | |
| SCHEMBL426848 | 0.65 | HCAR1 (0.49) | PIK3CDPI4KAPI4KBALDH1A1LMNA | |
| SCHEMBL28280597 | 0.63 | DHFR (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGPI4KB | |
| SCHEMBL28281757 | 0.62 | NFKB1 (0.38) | PIK3CAADORA2AADORA1KCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | claimed |
| EP-2964648-B1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2016-11-16 | — | — | EP | claimed |
| EP-2964648-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | Merck Patent GmbH (DE) | 2016-01-13 | — | — | EP | claimed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | claimed |
| WO-2014135245-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | claimed |
| EP-2964648-B1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2016-11-16 | — | — | EP | disclosed |
| EP-2964648-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | Merck Patent GmbH (DE) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014135245-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | EIF2AK4, GCN1, EIF4A2 | PIK3CD 3385/4885PIK3CA 1637/4885PIK3CB 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.